Products for Research Use Only
RegisterLogin

Izumerogant

CAT: 0804-HY-152851-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-152851-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Izumerogant (IMU-935) is an orally active RORγ/DHODH dual inhibitor with IC50s of 10 and 98 nM against RORγ and DHODH. Izumerogant efficiently blocks the replication of SARS-CoV-2, HCMV and HAdV5 with EC50 values between 3.6 and 17 nM. Izumerogant can be used for researching antiviral properties[1][2].
CAS Number
2299252-72-3
Product Name Alternative
IMU-935
UNSPSC
12352005
Target
CMV; Dihydroorotate Dehydrogenase; ROR; SARS-CoV
Type
Reference compound
Related Pathways
Anti-infection; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Infection
Assay Protocol
https://www.medchemexpress.com/izumerogant.html
Purity
99.95
Solubility
DMSO : 200 mg/mL (ultrasonic)
Smiles
FC1=CC=CC(Cl)=C1C2=NOC(C3=C(C(F)(F)F)N(CCC(C)(C)O)N=C3)=C2C4=NC=CC=N4
Molecular Formula
C22H18ClF4N5O2
Molecular Weight
495.86
References & Citations
[1]F Jakob, et al. Isoxazole-pyrazole derivatives and related compounds as IL-17 and IFN-γ inhibitors for treating autoimmune diseases and chronic inflammation: World Intellectual Property Organization, WO2019048541. 2019-03-14.|[2]Polasek TM, et al. Safety, Tolerability, and Pharmacokinetics of IMU-935, a Novel Inverse Agonist of Retinoic Acid Receptor-Related Orphan Nuclear Receptor γt: Results From a Double-Blind, Placebo-Controlled, First-in-Human Phase 1 Study. Clin Pharmacol Drug Dev. 2023 May;12 (5) :525-534.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Isoform
RORγ

Alternative Products

CatalogName
MBS5812241Izumerogant

Popular Products